PF-08653945

DRUG3 trials

Sponsors

Pfizer Inc., Pfizer

Conditions

Body WeightHealthyNutrition DisordersNutritional and Metabolic DiseasesObesityOvernutritionOverweightOverweight and/or Obesity

Phase 1

C6501003 - A Phase 1, Open-Label, Randomized, Single Dose, Parallel Group Study to Assess Relative Bioavailability of PF-08653945 When Administered Across Different Injection Sites in Adults With Overweight or Obesity

Not yet recruitingCTIS2026-526334-67-00

Pfizer Inc.chronic weight management and other weight-related co-morbidities

Target: 57Updated: 2026-07-01

A Study to Learn How the Study Medicine Called PF-08653945 is Taken up Into the Blood in Adults With Overweight or Obesity

RecruitingNCT07725809

PfizerHealthy, Obesity, Overweight

Start: 2026-07-23End: 2027-01-13Target: 57Updated: 2026-09-09

Phase 2

A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity

Active, not recruitingNCT07575932

PfizerBody Weight, Nutritional and Metabolic Diseases, Nutrition Disorders +5

Start: 2026-05-11End: 2028-01-05Updated: 2026-09-14